Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Translated article] Vemurafenib for the treatment of BRAF V600 mutated glioblastoma: A case report.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria - 1 Jan 2025

de la Fuente Villaverde Irene, Caso González Alicia, Carbajales Álvarez Mónica, Martínez Torrón Alba, Fernández Lastras Sergio, García Llano Juan Luis, Lozano Blázquez Ana

Abstract excerpt

INTRODUCTION: Glioblastoma is one of the most aggressive primary brain tumors with the worst prognosis. Few therapeutic options are currently available. Vemurafenib is a kinase inhibitor that demonstrated efficacy in clinical trials for the treatment of tumors with BRAF V600 mutation. Its experience of use in glioblastomas is very limited. We present the case of a patient diagnosed with BRAF V600 mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRAF gene

Share to Glioblastoma

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Source

Identifiers

PMID: 40681427
DOI: 10.1016/j.farma.2025.05.010

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Translated article] Vemurafenib for the treatment of BRAF V600 mutated glioblastoma: A case report.PMID 40681427Read ↗

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma.Semantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.Semantic proximity Read ↗

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Semantic proximity Read ↗

Effective Treatment of a BRAF V600E-Mutant Epithelioid Glioblastoma Patient By Vemurafenib: A Case ReportSemantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

[Progress of anti-tumor study based on BRAF].Semantic proximity Read ↗

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.Semantic proximity Read ↗

Vemurafenib: the first drug approved for BRAF-mutant cancer.Semantic proximity Read ↗

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.Semantic proximity Read ↗

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Semantic proximity Read ↗

Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.